LPAR1 and atherosclerosis: To assess the effect of LPA1/3 inhibition on atherosclerosis, LDLr−/− mice were injected intraperitoneally with either Ki16425 (5 mg/kg) or a vehicle-control for 6 weeks, (3x/week).